Kidney Function in People With Cystic Fibrosis in the Era of HEMT

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7+
SponsorUniversity of Virginia

About this trial

The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it becomes permanent. The study will compare these markers in people with CF over time and during the treatment of lung flare-ups. It will also compare the blood and urine samples obtained from people without CF. The comparison aims to better understand the impact of cystic fibrosis and its treatment on the kidneys, as well as to develop improved methods for preventing, diagnosing, and treating kidney issues associated with CF.

Eligibility criteria

Qualifiers

Outpatient CF Cohort

Diagnoses of Cystic Fibrosis

Age > 30 years old

Able to provide informed consent

Disqualifiers

Outpatient CF Cohort

History of any organ transplant

History of immunodeficiency

Previous or current cancer diagnoses

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

260 Participants
are grouped into 3 trial groups

Sponsors and collaborators